Acme United Corporation Achieves Its Best Year Ever Amid Tariff Volatility

In 2025, Acme United Corporation (US: ACU – $42.50) delivered record sales and earnings, achieving the strongest financial performance in its history despite a year marked by volatility and uncertainty. The Company navigated tariff disruptions, shifting customer demand, and global supply chain challenges to produce improved results across most of its key metrics.

For the quarter ended December 31, 2025, net sales rose to $47.5 million, compared to $45.9 million in the fourth quarter of 2024, representing a 3% increase. Net income for the quarter grew 10% to $1.9 million, or $0.46 per diluted share, compared to $1.7 million, or $0.41 per diluted share, in the prior-year period. Diluted earnings per share increased 12%.

For the full year ended December 31, 2025, net sales reached $196.5 million, up 1% from $194.5 million in 2024. Net income increased 2% to $10.2 million, or $2.49 per diluted share, compared to $10.0 million, or $2.45 per diluted share, in 2024.

Navigating Tariffs and Market Disruption

Chairman and CEO Walter C. Johnsen stated that the Company successfully navigated customer uncertainty and increased costs resulting from tariffs imposed in April 2025. These tariffs changed multiple times throughout the year and significantly disrupted retail activity, leading many customers to delay or cancel promotions.

When tariffs on Chinese goods were reduced from 145% to 30% in late April 2025, the Company’s teams in the United States and Asia responded rapidly as they shipped more than 50 containers within days.

At the same time, Acme worked with suppliers to open new factories in Vietnam, Thailand, and Malaysia, while expanding production in India and Egypt. Management negotiated cost reductions, secured lower freight rates, increased productivity in domestic plants, and implemented modest price increases to offset higher costs.

2025 Operational Highlights

Several initiatives strengthened the Company’s long-term competitive position. The first aid division introduced the RFID SmartCompliance Cabinet at the 2025 NSC Safety Congress & Expo. The RFID system is a patented automatic replenishment system that uses sensors to detect depleted or obsolete components in industrial first aid kits and that automatically generates refill orders. Customers typically save between 30% and 50% compared to traditional van-based delivery systems.

The Westcott brand expanded market share in cutting tools, particularly in the craft segment, leveraging patented nonstick technology to create differentiated products designed for cutting adhesive materials. The Company also grew its line of ceramic safety tools and increased sales of industrial cutting tools.

Investments in robotics at three U.S. based sites improved assembly efficiency and quality for first aid refill products. The Company also implemented new warehouse optimization software at its facility in Rocky Mount, streamlined inventory processes, and deployed drones for nightly inventory reconciliation.

In addition to the Tennessee facility acquisition, the Company purchased new automated processing equipment to support the expansion of its Spill Magic, bodily fluid kit, and blood-borne pathogen product lines.

Finally, in January 2026, the Company acquired My Medic, a leading direct-to-consumer supplier of advanced first aid and bleed control products in the United States. My Medic generated approximately $19 million in revenue in 2025 and was acquired for $18.7 million. With more than 500,000 social media followers, the brand provided a strong platform for expanded product offerings and distribution in the U.S. and Canada.

Financials & Balance Sheet

Selling, general and administrative (SG&A) expenses declined as a percentage of sales in the fourth quarter to 32%, or $15.2 million, compared to 34%, or $15.5 million, in the fourth quarter of 2024. For the full year, SG&A expenses were $62.7 million, or 32% of sales, consistent with the prior year.

	Three Months Ended December 31		Year Ended December 31
Amounts in $000’s	2025	2024	2025	2024
Net Sales	47,524	45,943	196,542	194,490
Cost of Goods Sold	29,376	28,178	119,132	118,139
S, G & A Expenses	15,247	15,483	62,685	62,211
Income (Loss) From Operations	2,901	2,282	14,725	14,140
Net Interest Expense	338	427	1,560	1,942
Other Income (Expenses)	(90)	8	(47)	95
Pre-Tax Income	2,473	1,863	13,118	12,293
Income Tax Expense (Benefit)	596	153	2,933	2,270
Net Income (Loss)	1,877	1,710	10,185	10,023
Earnings Per Share – Diluted	0.46	0.41	2.49	2.45
Shares Out. – Diluted	4,076	4,155	4,087	4,099
Most important income statement data for the quarters and full year ended December 31, 2025 and December 31, 2024. Source: Company Press Release

Gross margin for the fourth quarter was 38.2%, slightly below the 38.7% recorded in the same period of 2024. For the full year, gross margin improved modestly to 39.4% compared to 39.3% in the prior year.

Operating profit in the fourth quarter of 2025 increased 27% compared to the fourth quarter of 2024. Interest expense declined from $1.9 million in 2024 to $1.6 million in 2025 due to lower debt levels and reduced interest rates.

	Year Ended December 31
Amounts in $000’s	2025	2024
Cash and Cash Equivalents	3,596	6,399
Accounts Receivable	29,098	28,236
Inventories	59,852	56,254
Total Current Assets	96,195	95,460
Property and Equipment	38,541	31,653
Total Assets	170,998	162,170
Accounts Payable	8,066	9,005
Other Current Liabilities	12,906	11,866
Total Current Liabilities	22,872	22,872
Long Term Debt	11,853	17,606
Total Liabilities	53,387	55,190
Total Stockholder Equity	117,611	106,980
Most important balance sheet data for the periods ended December 31, 2025 and December 31, 2024. Source: Company Press Release

As of December 31, 2025, bank debt less cash stood at $18.1 million, compared to $21.5 million a year earlier. During 2025, the Company generated approximately $13.6 million in free cash flow. It distributed approximately $2.3 million in dividends, acquired a German cutting and sharpening product line for $1.6 million, and purchased a new 78,000-square-foot manufacturing and distribution facility in Mt. Pleasant, Tennessee for approximately $6 million to expand its Spill Magic business.

Segment Performance

In the United States segment, fourth-quarter net sales remained flat compared to the prior year, while full-year sales declined 1%. First aid and medical product sales were strong, but school and office product sales declined due to tariff-related order cancellations.

	Year Ended December 31
Amounts in $000’s	2025	2024
U.S.	165,031	166,152
Canada	15,175	13,261
Europe	16,336	15,077
Estimated sales per segment for the year ended December 31, 2025 (Source: Smallcaps Investment Research) and actual sales per segment for the year ended December 31, 2024 (Source: Company Filing)

European net sales increased 31% in U.S. dollars (22% in local currency) during the fourth quarter and rose 8% in U.S. dollars (4% in local currency) for the full year. Despite a weak overall economy, the Company gained market share in cutting tools. On October 1, 2025, its German subsidiary acquired Schmiedeglut, a direct-to-consumer cutting and sharpening supplier with annual sales of approximately $2 million. Acme Europe paid $1.6 million, and the acquisition contributed approximately $0.5 million in fourth-quarter sales.

In Canada, fourth-quarter net sales increased 14% in both U.S. dollars and local currency, and full-year sales rose 14% in U.S. dollars and 16% in local currency. Growth was driven by strong first aid sales, market share gains in industrial and retail channels, continued e-commerce expansion, and better-than-expected performance from Hawktree Solutions.

Positioning for the Future

Management emphasized that the Company exited 2025 with a strong balance sheet and continued to benefit from investments in distribution capacity, productivity improvements, and cost reduction initiatives. It continued to invest in advanced production equipment at its Med-Nap facility in Brooksville, Florida, expanded its quality assurance capabilities, and prepared to become a significant domestic supplier to the broader U.S. medical market.

As the Company moves into 2026, it expects growth in its first aid and medical segments and a normalization of retail merchandising and promotional activity. With expanded domestic production and diversified international sourcing, the Company believes it is well positioned for continued growth, both organically and through acquisitions. Smallcaps Recommendation: BUY.

Smallcaps.us Advice: Buy	Price Target: $53.47	Latest Company Report (pdf)
For important disclosures, please read our disclaimer.